Compare Stocks: LXRX, RCUS, DYN, and ZLAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$15.44 +1.6%	$22.31	$12.43 ▼ $27.31	$2.84B	1.12	3.77 million shs	4.38 million shs
LXRX Lexicon Pharmaceuticals	$1.74 -4.4%	$2.19	$1.10 ▼ $2.68	$809.82M	1.07	3.29 million shs	2.71 million shs
RCUS Arcus Biosciences	$24.73 +1.2%	$27.76	$13.61 ▼ $31.74	$3.11B	0.94	1.74 million shs	1.39 million shs
ZLAB Zai Lab	$25.62 +5.3%	$24.49	$15.96 ▼ $34.06	$2.77B	0.73	795,512 shs	787,299 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	0.00%	-5.18%	-37.40%	-33.45%	+16.39%
LXRX Lexicon Pharmaceuticals	0.00%	+1.39%	-18.75%	-21.55%	+29.08%
RCUS Arcus Biosciences	0.00%	-1.97%	-17.67%	-18.55%	+83.03%
ZLAB Zai Lab	0.00%	-2.60%	-7.24%	+27.52%	-27.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$15.44 +1.6%	$22.31	$12.43 ▼ $27.31	$2.84B	1.12	3.77 million shs	4.38 million shs
LXRX Lexicon Pharmaceuticals	$1.74 -4.4%	$2.19	$1.10 ▼ $2.68	$809.82M	1.07	3.29 million shs	2.71 million shs
RCUS Arcus Biosciences	$24.73 +1.2%	$27.76	$13.61 ▼ $31.74	$3.11B	0.94	1.74 million shs	1.39 million shs
ZLAB Zai Lab	$25.62 +5.3%	$24.49	$15.96 ▼ $34.06	$2.77B	0.73	795,512 shs	787,299 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	0.00%	-5.18%	-37.40%	-33.45%	+16.39%
LXRX Lexicon Pharmaceuticals	0.00%	+1.39%	-18.75%	-21.55%	+29.08%
RCUS Arcus Biosciences	0.00%	-1.97%	-17.67%	-18.55%	+83.03%
ZLAB Zai Lab	0.00%	-2.60%	-7.24%	+27.52%	-27.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	2.82	Moderate Buy	$33.07	114.19% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$5.70	227.59% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	54.85% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	45.39% Upside

Current Analyst Ratings Breakdown

Latest LXRX, RCUS, DYN, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$37.00
9/30/2026	DYN Dyne Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	DYN Dyne Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/30/2026	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00
9/30/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $32.00
9/30/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$43.00
9/29/2026	DYN Dyne Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$47.00
9/28/2026	LXRX Lexicon Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	15.55	N/A	N/A	$0.30 per share	5.80
RCUS Arcus Biosciences	$247M	12.75	N/A	N/A	$5.84 per share	4.24
ZLAB Zai Lab	$460.16M	6.33	N/A	N/A	$6.39 per share	4.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest LXRX, RCUS, DYN, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/27/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8769	N/A	N/A	N/A	$11.14 million	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/29/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	0.28	12.02	12.02
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
RCUS Arcus Biosciences	0.22	3.82	3.82
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
LXRX Lexicon Pharmaceuticals	74.70%
RCUS Arcus Biosciences	92.89%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	9.46%
LXRX Lexicon Pharmaceuticals	14.00%
RCUS Arcus Biosciences	7.60%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

LXRX, RCUS, DYN, and ZLAB Headlines

Recent News About These Companies

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

October 4 at 10:02 AM | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

October 2 at 12:59 PM | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026 | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Bumped Up to "Hold" by Wall Street Zen

September 26, 2026 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Seven Fleet Capital Management LP Acquires 58,158 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

September 5, 2026 | marketbeat.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LXRX, RCUS, DYN, and ZLAB Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$15.44 +0.24 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$15.63 +0.19 (+1.23%)

As of 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.74 -0.08 (-4.40%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.04 (+2.30%)

As of 07:30 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Arcus Biosciences NYSE:RCUS

$24.73 +0.29 (+1.20%)

Closing price 03:59 PM Eastern

Extended Trading

$24.74 +0.01 (+0.04%)

As of 07:31 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zai Lab NASDAQ:ZLAB

$25.62 +1.29 (+5.30%)

Closing price 04:00 PM Eastern

Extended Trading

$25.55 -0.07 (-0.27%)

As of 07:32 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXRX, RCUS, DYN, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXRX, RCUS, DYN, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXRX, RCUS, DYN, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LXRX, RCUS, DYN, and ZLAB Company Descriptions

Dyne Therapeutics NASDAQ:DYN

Lexicon Pharmaceuticals NASDAQ:LXRX

Arcus Biosciences NYSE:RCUS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXRX, RCUS, DYN, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXRX, RCUS, DYN, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXRX, RCUS, DYN, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LXRX, RCUS, DYN, and ZLAB Company Descriptions

Dyne Therapeutics NASDAQ:DYN

Lexicon Pharmaceuticals NASDAQ:LXRX

Arcus Biosciences NYSE:RCUS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools